Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

BIZARRE: Neogenomics stock just turned its first profit creating an optimal entry point - You Need To See This

  • NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high.
  • Shares are up more than 170% over the past 52 weeks.
  • NEO maintains a 100% “Buy” technical opinion from Barchart.
  • Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and recent profitability marking a compelling entry point.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.